Details for New Drug Application (NDA): 215449
✉ Email this page to a colleague
The generic ingredient in TOPIRAMATE is topiramate. There are twenty-six drug master file entries for this compound. Fifty-four suppliers are listed for this compound. Additional details are available on the topiramate profile page.
Summary for 215449
Tradename: | TOPIRAMATE |
Applicant: | Aurobindo Pharma Ltd |
Ingredient: | topiramate |
Patents: | 0 |
Pharmacology for NDA: 215449
Mechanism of Action | Cytochrome P450 2C19 Inhibitors Cytochrome P450 3A4 Inducers |
Physiological Effect | Decreased Central Nervous System Disorganized Electrical Activity |
Suppliers and Packaging for NDA: 215449
Tradename | Generic Name | Dosage | NDA | Application Type | Supplier | National Drug Code | Package Code | Package |
---|---|---|---|---|---|---|---|---|
TOPIRAMATE | topiramate | CAPSULE;ORAL | 215449 | ANDA | Aurobindo Pharma Limited | 59651-452 | 59651-452-60 | 60 CAPSULE in 1 BOTTLE (59651-452-60) |
TOPIRAMATE | topiramate | CAPSULE;ORAL | 215449 | ANDA | Aurobindo Pharma Limited | 59651-453 | 59651-453-60 | 60 CAPSULE in 1 BOTTLE (59651-453-60) |
Profile for product number 001
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 15MG | ||||
Approval Date: | Sep 27, 2023 | TE: | AB | RLD: | No |
Profile for product number 002
Active Rx/OTC/Discontinued: | RX | Dosage: | CAPSULE;ORAL | Strength | 25MG | ||||
Approval Date: | Sep 27, 2023 | TE: | AB | RLD: | No |
Complete Access Available with Subscription